- Home
- ASTC vs PHGE Comparison
ASTC vs PHGE Comparison
Compare ASTC & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTC
- PHGE
- Stock Information
- Founded
- ASTC 1984
- PHGE 2015
- Country
- ASTC United States
- PHGE Israel
- Employees
- ASTC N/A
- PHGE N/A
- Industry
- ASTC Biotechnology: Laboratory Analytical Instruments
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- ASTC Industrials
- PHGE Health Care
- Exchange
- ASTC Nasdaq
- PHGE Nasdaq
- Market Cap
- ASTC 9.8M
- PHGE 11.0M
- IPO Year
- ASTC 1995
- PHGE N/A
- Fundamental
- Price
- ASTC $5.63
- PHGE $0.42
- Analyst Decision
- ASTC
- PHGE Strong Buy
- Analyst Count
- ASTC 0
- PHGE 1
- Target Price
- ASTC N/A
- PHGE $15.00
- AVG Volume (30 Days)
- ASTC 8.6K
- PHGE 265.4K
- Earning Date
- ASTC 05-13-2025
- PHGE 08-13-2025
- Dividend Yield
- ASTC N/A
- PHGE N/A
- EPS Growth
- ASTC N/A
- PHGE N/A
- EPS
- ASTC N/A
- PHGE N/A
- Revenue
- ASTC $903,000.00
- PHGE N/A
- Revenue This Year
- ASTC N/A
- PHGE N/A
- Revenue Next Year
- ASTC N/A
- PHGE N/A
- P/E Ratio
- ASTC N/A
- PHGE N/A
- Revenue Growth
- ASTC N/A
- PHGE N/A
- 52 Week Low
- ASTC $5.39
- PHGE $0.34
- 52 Week High
- ASTC $12.29
- PHGE $3.86
- Technical
- Relative Strength Index (RSI)
- ASTC 43.43
- PHGE 39.46
- Support Level
- ASTC $5.50
- PHGE $0.42
- Resistance Level
- ASTC $5.73
- PHGE $0.47
- Average True Range (ATR)
- ASTC 0.27
- PHGE 0.05
- MACD
- ASTC -0.01
- PHGE 0.00
- Stochastic Oscillator
- ASTC 14.29
- PHGE 47.00
About ASTC Astrotech Corporation (DE)
Astrotech Corp is a science and technology development company. The firm invents, acquires, and commercializes technological innovations sourced from internal research, universities, laboratories, and research institutions. The 1st Detect develops, manufactures, and sells chemical analyzers for use in the airport security, military, and breath analysis markets. AgLAB develops a series of mass spectrometers for use in the agriculture market.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).